Description
Indication & Scope
- Mechanism
Bind with tumor cell DNA to form intra-strand and inter-strand cross-links, damage DNA and inhibit tumor cell replication - Drug class
Platinum-based cytotoxic chemotherapeutic agent / Alkylating-like anti-tumor drug - Clinical use
Advanced ovarian cancer, non-small cell lung cancer, head and neck squamous cell carcinoma
| Generic Name | Carboplatin Injection |
| Brand Name | Paraplatin® |
| Ingredient | Carboplatin |
| Dosage Form | Injection |
| Package | 150mg/15ml/vial |
| Conditions Treated | Locally advanced or metastatic epithelial ovarian cancer, for first-line combined chemotherapy and second-line treatment after disease progression; Locally advanced or metastatic non-small cell lung cancer, used in combination chemotherapy regimens; Squamous cell carcinoma of head and neck |
| Taboos | Severe myelosuppression; severe renal impairment; hypersensitivity to carboplatin, cisplatin or any platinum-based anti-tumor drugs and excipients; pregnant women |
| Place of origin | Latina,Italy |
| Priscription Type | Prescription drug (Rx) |
| Storage Conditions | Store at 2℃-8℃, protected from light, sealed |
| Manufacturer | Latina Pharma S.p.A. |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | HJ20171063 |
| Date of Approval | April 14, 2026 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Calculate dosage according to patient’s creatinine clearance rate and target AUC value; dilute with 5% glucose injection for intravenous infusion over 15–60 minutes, do not administer by rapid bolus injection
Time: Administer once every 21–28 days as a chemotherapy cycle; closely monitor blood cell count before each cycle
Interaction: Avoid concomitant use with other nephrotoxic drugs; caution with myelosuppressive agents, additive hematological toxicity will occur
Side effects: Thrombocytopenia, neutropenia, anemia, mild nausea and vomiting, renal function damage, peripheral neuropathy, ototoxicity, hypersensitivity reactions
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the core anti-tumor mechanism of carboplatin?
Cross-link with tumor cell DNA to damage DNA and block cell division.
What is the difference between carboplatin and cisplatin?
Carboplatin has weaker nephrotoxicity and emetic response, more obvious thrombocytopenia.
What solvent is used to dilute carboplatin?
5% glucose injection, normal saline is not recommended.
What is the main dose-limiting adverse reaction of carboplatin?
Thrombocytopenia (bone marrow suppression).
Paraplatin® | Carboplatin Injection | EOC,NSCLC and HNSCC | DengYueRX
INN: Carboplatin
Indications: EOC (Epithelial Ovarian Cancer), NSCLC (non-small cell lung cancer ) and HNSCC (Head and Neck Squamous Cell Carcinoma)
Dosage Form: Injection
Strength: 150mg/15ml/Vial
Original price was: $39.41.$33.50Current price is: $33.50.
